Thymogen vs BPC-157
Side-by-side comparison of Thymogen and BPC-157: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
Thymogen
BPC-157
Thymogen
Thymogen (also transliterated Timogen or ╨ó╨╕╨╝╨╛╨│╨╡╨╜) is a synthetic dipeptide — glutamyl-tryptophan (Glu-Trp, or EW) — developed by the St Petersburg Institute of Bioregulation and Gerontology under Professor…
No vendor price on file.
Full Thymogen profileBPC-157
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of human gastric juice…
Lowest listed price: $34.99 across 15 listings
Full BPC-157 profileSide-by-side comparison
| Attribute | Thymogen | BPC-157 |
|---|---|---|
| Category | Recovery | Injury, Repair & Recovery |
| Research Stage | Approved in Russia / not Western-validated | Preclinical |
| Mechanism of Action | Thymogen's proposed mechanism is best understood in the context of thymic biology and the broader class of thymic peptide immunomodulators. The thymus is the primary organ of T-cell maturation - T-cell progenitors from bone marrow migrate to the thymus,… | Nitric Oxide (NO) System Modulation BPC-157 exerts a central integrative effect through modulation of the nitric oxide system. Studies by Seiwerth et al. (2022) demonstrated that BPC-157 counteracts both NO-excess and NO-deficiency states, functioning as a… |
| Half-Life | short; not well characterized | Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived. |
| Typical Dose Range | 50-100 mcg intranasal per nostril 1-2x/day, or 100 mcg SC once daily; 10-day courses, 2-4x/year | 200-500 mcg subcutaneous 1-2x daily (community protocols); 1-10 mcg/kg in animal studies |
| Dosing Frequency | — | Twice daily (AM and PM), an empirical schedule not derived from serum levels; once daily acceptable |
| Administration | — | Subcutaneous, Oral, Intraperitoneal, Intravenous |
| Side Effects | Thymogen's side-effect profile in the Russian clinical literature is described as mild and infrequent, consistent with its long history of registered pharmaceutical use in Russia. Users should weight this with modest skepticism given the limitations of the… | Not established as well tolerated: a 2025 systematic review found no clinical safety data (PMID: 40756949), and FDA's 2026 review found three adverse event reports through 4 December 2025, all with injected BPC-157 (an injection-site reaction, shortness of… |
| Molecular Weight | ~333.3 g/mol (Glu-Trp) | 1419.5 g/mol (average); molecular formula C62H98N16O22 |
| Common Vial Sizes | — | 5mg, 10mg |
Price History
7 data points- OF
- BM
- Half Nattys
- LB
- Ion Peptide
- BHG Labs
Thymogen: potential benefits
- Immune system modulation
- Thymic function restoration
- Enhanced T-cell immunity
- Immune anti-aging support
BPC-157: potential benefits
- Accelerated tendon and ligament healing with improved biomechanical strength in preclinical soft-tissue injury models (PMID: 30915550)
- Gastric and GI mucosal cytoprotection against ethanol-induced lesions, mediated in part by the nitric oxide system (PMID: 30279308)
- Healing of cysteamine-induced colitis and colon anastomosis in preclinical inflammatory bowel disease models (PMID: 24304574)
- Neuroprotection with dopaminergic and nitric oxide-system modulation in central nervous system injury models such as stroke and dopamine-receptor blockade (PMID: 34380875)
- Promotion of angiogenesis via VEGFR2 up-regulation, internalization, and VEGFR2-Akt-eNOS signaling in rat hind-limb ischemia and endothelial assays (PMID: 27847966)
- Tendon fibroblast outgrowth, cell survival, and migration through FAK-paxillin pathway activation (PMID: 21030672)
- Growth hormone receptor up-regulation in tendon fibroblasts, potentiating growth hormone's proliferative effect (PMID: 25415472)
- Nitric oxide-system interaction with endothelium protection, angiogenesis, and EGR-1-mediated growth-factor and collagen expression (PMID: 22300085)
Frequently asked
What's the difference between Thymogen and BPC-157?
Thymogen is a recovery that thymogen's proposed mechanism is best understood in the context of thymic biology and the broader class of thymic peptide immunomodulators. the thymus is the primary organ of…. BPC-157 is a injury, repair & recovery that nitric oxide (no) system modulation bpc-157 exerts a central integrative effect through modulation of the nitric oxide system. studies by seiwerth et al. (2022) demonstrated that…. The two differ in mechanism, half-life (short; not well characterized vs Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived.), and typical dose range.
Which has the longer half-life, Thymogen or BPC-157?
Thymogen has a half-life of short; not well characterized. BPC-157 has a half-life of Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived.. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Can you stack Thymogen and BPC-157?
Stacking depends on mechanism overlap, safety profile, and goals. Thymogen and BPC-157 should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy Thymogen or BPC-157
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.